Ocrelizumab in multiple sclerosis: Risks and benefits - Author's reply

摘要

We agree with Abhijit Chaudhuri that a phase 2 proof-of-concept study cannot provide definite evidence about the safety profile of a new compound. What we reported is that the benefit/ risk profile noted over 48 weeks and in a limited number of patients was positive. Our paper concludes by underlining the need for larger and longer-term studies to better inform the benefit/risk profile of ocrelizumab.